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A B S T R A C T
Evaluation of the health-related quality of life (HRQoL) in patients with respiratory diseases has been increasingly
included into regular clinical studies, and HRQL in sarcoidosis has been evaluated since not a long ago. The aim of the
study was to evaluate HRQoL in patients with sarcoidosis regarding gender differences, pre and after therapy. We inves-
tigated 202 pathohistologically verified sarcoidosis patients (154 female and 48 male) without comorbidities. HRQL was
assessed by the disease-specific Sarcoidosis Health Questionnaire (SHQ), which contains 29 items, and cover three do-
mains: everyday functioning, physical activities and emotional state. Total score, as well as the scores for each SHQ do-
mains were calculated. HRQoL was estimated pre and after three months of therapy. At the study start, the lowest score
value for the whole group was reported in SHQ emotional state domain (4.24), and the highest in domain of physical
functioning (4.7). After three months, the lowest values were reported in domain of everyday activities, while the highest
scores were found in emotional domain; all SHQ scores increased, but reached the statistical significance only in the ev-
eryday functioning and the physical activities domains. Analyzing mean SHQ scores in male and female sarcoidosis pts
before therapy we found high statistically lower emotional and total score in female pts, as well as lower physical score.
After the three months therapy we found high statistical difference in physical domain (i.e.women had lower physical
score than men). Female sarcoidosis pts showed lower emotional, physical and total score before therapy. After the three-
-month therapy we found that women had lower physical score than men. SHQ showed good measurement properties
both in the cross-sectional and longitudinal assessment of sarcoidosis patients.
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Introduction
Sarcoidosis is a chronic disease which largely inter-
feres with physical, emotional and social aspects of pa-
tients’ life, both in working environment and everyday
activities¹. It is a condition developing in younger adults
(20–40 years). In this age period, it is certainly difficult to
face with multi-organ disease of unknown etiology and
unpredictable progress2,3. Chronic condition in so young
age might result in working and social problems, espe-
cially if a person looked healthy4. Patients perceive the
condition of their affected health and, by insight into
their quality of life, they often may suggest the present con-
dition of their disease as well as the success of treatment.
The studies dealing with sarcoidosis, have, until re-
cently, estimated the disease exclusively by focusing on
pulmonary manifestations viewed on X-ray films, and
values of the lung functions and gas exchange5–7. How-
ever, these clinical variables are not correlated strongly
with long-term outcome of disease8,9, do not consider psy-
chological discomforts of patients10 and other organ sys-
tem difficulties that may have effect on satisfaction of pa-
tients with their life style. More important is that these
studies have found poor correlation with the way pa-
tients see their quality of life11,12.
Evaluation of the health-related quality of life (HRQoL)
in patients with respiratory diseases has been increas-
ingly included into regular clinical studies. Yet, the refer-
ence literature reports a small number of evaluations of
the HRQoL in sarcoidosis. So far, available literature has
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failed to demonstrate data that analyze follow-up of
changes in the HRQoL after therapeutical regimes.
Materials and Methods
The aim of the study was to evaluate HRQoL in pa-
tients with sarcoidosis regarding gender differences, pre
and after therapy. The study included 202 pts (154 fe-
male and 48 male), median age 46 (range 18–75) years,
examined and treated at the Institute for Pulmonary
Diseases and TB, Clinical Center of Serbia, Belgrade.
Criterion for patients’ entering the study was patho-
histologicaly verified sarcoidosis of the lungs or any other
organ. A Case Control Etiologic Study of Sarcoidosis (AC-
CESS) criteria of the American Association of Cardio-
pulmonary and Hematological Studies were used for di-
agnosis of sarcoidosis in other organs13. According to
Paris classification criteria, and on the basis of poste-
rior-anterior radiography of the chest, the form of pul-
monary sarcoidosis was divided into 5 stages: 0, I, II, III
and IV21.
In order to assess HRQoL in sarcoidosis patients we
used Sarcoidosis Health Questionnaire (SHQ) which is
the first disease specific questionnaire for HRQoL analy-
sis in sarcoidosis. It consists of 29 questions which cover
three fields: everyday functioning, physical activities and
emotional state. The response scales range 1 (all of the
time) to 7 (none of the time). Reliability and validity of
this questionnaire appear to be very good14. The ques-
tionnaire was filled by patients themselves pre and after
three months therapy.
Statistical Analysis
SHQ scores were calculated by original calculator
made in Microsoft Excel, which was obtained directly
from the author of questionnaire (Dr Christopher Cox,
University of South Carolina, USA). Statistical analysis
was performed using SPSS version. 12 for Windows
(SPSS Inc., Richmond, USA). The following methods
were used: descriptive statistics, Student’s test for inde-
pendent samples, Student’s test for paired samples, one-
way ANOVA and Pearson’s correlation coefficient. Levels
of statistical significance were determined at p<0.05 (*)
and p<0.01 (**).
Results
The demographic characteristics of sarcoidosis pa-
tients are listed in Table 1. Radiographic stage of sar-
coidosis is presented in Table 2. In studied group of 202
sarcoidosis patients, the largest number of patients was
in stage I group: 21 male (43.7%) and 64 (41.5%) female.
Substantially lesser patients were found in stage II: 17
male (35.4%) and 56 (36.3%) female, while the small
number was reported in stages III, IV and 0. There was
no statistical difference between male and female pa-
tients according to the radiographic stage of the disease.
Mean SHQ scores before the applied therapy in the
whole group are demonstrated in Figure 1. It was noted
that the lowest value was reported in domain of emo-
tional score (4.24±0.7), and the highest in domain of
physical score (4.7±1.0). The score results three months
after therapy are presented in the same Figure. This
time, the lowest values were reported in domain of every-
day activities (4.55±0.9) while the highest scores were
found in emotional domain (6.36±2.65).
Analyzing mean SHQ scores in male and female sar-
coidosis patients before therapy we found statistically
significant lower emotional and total score in female
sarcoidosis patients (5.01±0.9 vs. 4.60±1.0 and 4.47±0.7
vs. 4.17±0.7, respectively; p<0.05 in both cases), as well
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Fig. 1. Mean values of SHQ scores before and after treatment.
TABLE 1
DEMOGRAPHICS
Males Females Smokers Non-smokers Ex-smokers
N 48 154 19 167 16



















Fig. 2. Comparison of mean values of SHQ scores between gen-
der before treatment.
as lower physical score (4.69±0.6 vs. 4.38±0.7; p<0.01).
After the three months therapy we found highly signifi-
cant difference in mean values of physical domain: i.e.
women had lower physical score than men (5.20±1.0 vs.
4.77±1.1; p<0.01) (Figure 2). Differences in emotional do-
main and daily activities are not statistically significant.
Discussion
It is well known that gender can influence the quality
of life. This is especially important in sarcoidosis where
the majority of patients are female.
Our results show lower emotional, physical and total
SHQ scores in female than in male sarcoidosis patients
before applying therapy regimes. This might lead to a
conclusion that male sarcoidosis patients showed signifi-
cant lower emotional dysfunction as well as they might
be better adopted to physical limitations that were pres-
ent at the moment of establishing the diagnose (fatigue,
ankle pain, etc.). Similar results were found in the inves-
tigation of De Vries et al.15 as well as Michielsen et al.16
who showed bigger percentage of women with fatigue.
These investigations were performed on Dutch and Cro-
atian sarcoidosis patients. Those results do not agree
with Wirnsberger’s investigation17 which showed no gen-
der differences considering fatigue. The results of Wirn-
sberger et al. suggest that men complain on fatigue at the
same level as women, but only when their disease is
multisymptom. In that case, fatigue is the major indica-
tor of disease severity.
Chang et al investigated depression in sarcoidosis pa-
tients and found that female patients expressed more de-
pression symptoms than male18. But, the authors show
critical attitude about that data, especially considering
epidemiologic study of Frerich et al., who found greater
percentage of female with depression in the whole popu-
lation of Los Angeles19.
After the three months of therapy, female patients ex-
pressed lower physical scores than male. The explanation
might be found in the fact that sarcoidosis is more often
in women and in their case the disease is often expressed
with chronic and severe forms of disease. So, it is logical
explanation that physical limitations in female patienst
showed slower and more difficult recovery than in male
sarcoidosis patients.
The largest study on 1026 sarcoidosis patients was
performed by De Vries et al.20 and was conducted with
the aim to examine gender differences in quality of life of
sarcoidosis patients. The authors found that women ex-
perienced more symptoms than men. Female patients
had worse physical and psychological aspects of HRQoL.
To the best of our knowledge, our study is the first
one that analyzes HRQoL of such large number of sar-
coidosis patients, and follows up the HRQoL pre and af-
ter therapy. However, it has certain limitations. First, we
used only one instrument for measuring HRQoL. Sec-
ondly, for SHQ minimal statistical difference was not es-
tablished yet. And finally, three months of therapy might
not be enough to identify real differences in HRQoL in
sarcoidosis patients.
In conclusion we can say that analysis of quality of life
may enhance the communication between the clinicians
and patients. We consider SHQ useful instrument for
evaluating of HRQoL in sarcoidosis patients.
Our study is contribution in helping to understand
which are the causes of differences in HRQoL in female
and male, whether they are consequence of the different
hormonal/genetic status, or life style. We agree with De
Vries et al.20 that future studies in this field are needed.
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Fig. 3. Comparison of mean values of SHQ scores between gender
after treatment.
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KVALITETA @IVOTA OBZIROM NA SPOL KOD SARKOIDOZE
S A @ E T A K
Evaluacija sa zdravljem povezane kvalitete `ivota (engl. health-related quality of life (HRQoL)) kod pacijenata sa
respiratornim bolestima se sve vi{e uklju~uje u uobi~ajene klini~ke studije pa je tako HRQL kod sarkoidoze tek nedavno
evaluiran. Cilj studije je evaluirati HRQoL kod pacijenata obzirom na spolne razlike, prije te nakon terapije. Istra`ili
smo 202 pacijenta (154 `enska i 48 mu{ka) sa patohistolo{ki potvr|enom sarkoidozom bez komorbiditeta. HRQL je
odre|en prema bole{}u odre|enim upitnikom za sarkoidozu (engl. Sarcoidosis Health Questionnaire (SHQ)) koji se
sastoji od 29 stavaka a koji pokrivaju tri domene: svakodnevno funkcioniranje, tjelesne aktivnosti i emocionalno stanje.
Izra~unati su ukupni bodovi, kao i bodovi za pojedina~nu domenu. Procjenjen je HRQoL koji sadr`i 29 jedinica te
pokriva tri domene: svakodnevno funkcioniranje, fizi~ka aktivnost i emocionalno stanje. Izra~unat je ukupan rezultat,
uklju~uju}i i rezultate za svaku SHQ domenu. HRQoL je odre|en prije i poslije tromjese~ne terapije. Na po~etku istra`i-
vanja, najni`a vrijednost za cijelu grupu izra~unata je u SHQ u domeni emocionalnog stanja (4,24), a najvi{a u domeni
fizi~kog funkcioniranja (4,7). Nakon tri mjeseca, najni`e vrijednosti izra~unate su u domeni svakodnevnih aktivnosti, a
najvi{e u emocionalnoj domeni; svi SHQ rezultati su narasli, ali statisti~ku zna~ajnost su postigli tek u domenama
svakodnevnih aktivnosti i fizi~kih aktivnosti. Analiziraju}i glavne SHQ rezultate sarkoidoze kod mu{karaca i `ena prije
terapije prona|en je visok statisti~ki ni`i emocionalni i ukupni rezultat u `enskim bodovima, jednako kao i rezultatima
tjelesnih aktivnosti. Nakon tromjese~ne terapije pokazuje se visoka statisti~ka razli~itost u domeni tjelesnih aktivnosti
(npr. `ene su imale ni`i fizi~ki rezultat od mu{karaca). Sarkoidoza kod `ena prije terapije pokazuje ni`e emocionalne,
tjelesne i ukupne rezultate. Nakon tromjese~ne terapije `ene imaju ni`i rezultat tjelesnih aktivnosti od mu{karaca.
SHQ pokazuje dobre karakteristike mjerenja i u popre~nim kao i u longitudinalnim pristupima istra`ivanja pacijenata
oboljelih od sarkoidoze.
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